Sialorrhea in Parkinson's disease: A review

A significant number of patients with Parkinson's disease (PD) experience sialorrhea. This problem can cause social embarrassment, and because saliva pools in the mouth, may lead to aspiration pneumonia. Sialorrhea in PD is thought to be caused by impaired or infrequent swallowing, rather than hypersecretion. Oral medications, botulinum toxin injections, surgical interventions, radiotherapy, speech therapy, and trials of devices may be used to treat sialorrhea in PD, but few controlled trials have been published. This article reviews current knowledge regarding the frequency, etiology, assessment, and treatment of sialorrhea in PD. © 2007 Movement Disorder Society

[1]  L. Schneyer,et al.  Rate of secretion by exogenously stimulated salivary gland pairs of man. , 1955, Journal of applied physiology.

[2]  O. Doğu,et al.  Ultrasound-guided versus ‘blind’ intraparotid injections of botulinum toxin-A for the treatment of sialorrhoea in patients with Parkinson’s disease , 2004, Clinical Neurology and Neurosurgery.

[3]  W. Jost.  Treatment of drooling in Parkinson's disease with botulinum toxin , 1999, Movement disorders : official journal of the Movement Disorder Society.

[4]  W. Ondo,et al.  A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson’s disease , 2004, Neurology.

[5]  S. Fox,et al.  Ipratropium bromide spray as treatment for sialorrhea in Parkinson's disease , 2007, Movement disorders : official journal of the Movement Disorder Society.

[6]  M. Eadie,et al.  ALIMENTARY DISORDER IN PARKINSONISM. , 1965, Australasian annals of medicine.

[7]  Eadie Mj,et al.  ALIMENTARY DISORDER IN PARKINSONISM. , 1965 .

[8]  R. Feinmesser,et al.  Bilateral submandibular gland excision with parotid duct ligation for treatment of sialorrhea in children: long-term results. , 2002, Archives of otolaryngology--head & neck surgery.

[9]  I. Odderson,et al.  Quantitative Reduction of Saliva Production with Botulinum Toxin Type B Injection into the Salivary Glands , 2005, Neurorehabilitation and neural repair.

[10]  J. Montastruc,et al.  Yohimbine increases human salivary secretion. , 1989, British journal of clinical pharmacology.

[11]  E. Brodtkorb,et al.  Transdermal scopolamine in drooling. , 2008, Journal of mental deficiency research.

[12]  P. Martínez-Martín,et al.  Unified Parkinson's disease rating scale characteristics and structure , 1994, Movement disorders : official journal of the Movement Disorder Society.

[13]  D.S.P. C.C.C.-Sp Nancy Thomas-Stonell B.Sc.,et al.  Three treatment approaches and clinical factors in the reduction of drooling , 2006, Dysphagia.

[14]  A. Kupsch,et al.  A randomized trial of botulinum toxin A for treatment of drooling , 2003, Neurology.

[15]  J. Jankovic,et al.  Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia , 2005, Neurology.

[16]  I. Cook,et al.  Mechanisms of oral-pharyngeal dysphagia in patients with Parkinson's disease. , 1996, Gastroenterology.

[17]  A. Shekhar,et al.  Guanfacine treatment of clozapine-induced sialorrhea. , 2004, Journal of clinical psychopharmacology.

[18]  L. Stalpers,et al.  Results of radiotherapy for drooling in amyotrophic lateral sclerosis. , 2002, Neurology.

[19]  O. Rascol,et al.  A study of salivary secretion in Parkinson's disease. , 1999, Clinical neuropharmacology.

[20]  Houeto Jean-Luc.  [Parkinson's disease]. , 2022, La Revue du praticien.

[21]  S. Humphrey,et al.  A review of saliva: normal composition, flow, and function. , 2001, The Journal of prosthetic dentistry.

[22]  Andrew M. Johnson,et al.  Sublingual Atropine for sialorrhea secondary to parkinsonism: A pilot study , 2002, Movement disorders : official journal of the Movement Disorder Society.

[23]  W. M. Mullins,et al.  Long‐Term Follow‐Up of Tympanic Neurectomy for Sialorrhea , 1979, The Laryngoscope.

[24]  A. Stiggelbout,et al.  Systematic evaluation of rating scales for impairment and disability in Parkinson's disease , 2002, Movement disorders : official journal of the Movement Disorder Society.

[25]  B. Winsberg,et al.  EFFICACY OF BENZTROPINE THERAPY FOR DROOLING , 1989, Developmental medicine and child neurology.

[26]  M. Porta,et al.  Treatment of sialorrhoea with ultrasound guided botulinum toxin type A injection in patients with neurological disorders , 2001, Journal of neurology, neurosurgery, and psychiatry.

[27]  P. Chait,et al.  Saliva control issues in the neurologically challenged. A 30 year experience in team management. , 2006, International journal of pediatric otorhinolaryngology.

[28]  A. Friedman,et al.  Quantitative assessment of parkinsonian sialorrhea and results of treatment with botulinum toxin. , 2001, Parkinsonism & related disorders.

[29]  M. Guenot,et al.  Subthalamic nucleus stimulation in Parkinson's disease , 2002, Journal of Neurology.

[30]  Pei-Ning Wang,et al.  Swallowing difficulty in Parkinson's disease , 1997, Clinical Neurology and Neurosurgery.

[31]  M. Guenot,et al.  Subthalamic nucleus stimulation in Parkinson’s disease , 2002, Journal of Neurology.

[32]  W. Edgar.  Saliva and dental health. Clinical implications of saliva: report of a consensus meeting , 1990, British Dental Journal.

[33]  R. Jenkins,et al.  Crossover Clinical Trial of Benapryzine and Trihexyphenidyl in Parkinsonian Patients , 1975, Journal of clinical pharmacology.

[34]  K Turner,et al.  Drooling in Parkinson's disease: a novel speech and language therapy intervention. , 2001, International journal of language & communication disorders.

[35]  K. Marder,et al.  Reliability of patient completion of the historical section of the unified Parkinson's disease rating scale , 1996, Movement disorders : official journal of the Movement Disorder Society.

[36]  H. W. Boyce,et al.  Sialorrhea: a review of a vexing, often unrecognized sign of oropharyngeal and esophageal disease. , 2005, Journal of clinical gastroenterology.

[37]  M. Panisset,et al.  Salivary production in Parkinson's disease , 2005, Movement disorders : official journal of the Movement Disorder Society.

[38]  A. Lang,et al.  Translation of nondopaminergic treatments for levodopa‐induced dyskinesia from MPTP‐lesioned nonhuman primates to phase IIa clinical studies: Keys to success and roads to failure , 2006, Movement disorders : official journal of the Movement Disorder Society.

[39]  Gross Cw,et al.  Long-term follow-up of tympanic neurectomy for sialorrhea. , 1979 .

[40]  J. Saint-Cyr,et al.  Long-term follow up of bilateral deep brain stimulation of the subthalamic nucleus in patients with advanced Parkinson disease. , 2003, Journal of neurosurgery.

[41]  A. Panarese,et al.  Outcomes of submandibular duct re-implantation for sialorrhoea. , 2001, Clinical otolaryngology and allied sciences.

[42]  D. Lewis,et al.  TRANSDERMAL SCOPOLAMINE FOR REDUCTION OF DROOLING IN DEVELOPMENTALLY DELAYED CHILDREN , 1994, Developmental medicine and child neurology.

[43]  J. Perlmutter,et al.  Swallowing abnormalities and their response to treatment in Parkinson's disease , 1989, Neurology.

[44]  A. Buchman,et al.  Botulinum Toxin Injections for Children With Excessive Drooling , 2005, Journal of child neurology.

[45]  H. Grönberg,et al.  External radiation of the parotid glands significantly reduces drooling in patients with motor neurone disease with bulbar paresis , 2001, Journal of the Neurological Sciences.

[46]  Speirs Rl.  SALIVA AND DENTAL HEALTH , 1984 .

[47]  A. Benabid,et al.  Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. , 2003, The New England journal of medicine.

[48]  J. Perlmutter,et al.  Botulinum toxin B reduces sialorrhea in parkinsonism , 2003, Movement disorders : official journal of the Movement Disorder Society.

[49]  A. Lees,et al.  Botulinum toxin A as treatment for drooling saliva in PD. , 2000, Neurology.

[50]  E. Quigley,et al.  Gastrointestinal dysfunction in Parkinson's disease , 1992, Neurology.

[51]  S. Bachrach,et al.  Treatment of sialorrhea with glycopyrrolate: A double-blind, dose-ranging study. , 2000, Archives of pediatrics & adolescent medicine.

[52]  M. C. Kagel,et al.  Pharyngo-Esophageal Dysphagia in Parkinson's Disease , 1997, Dysphagia.

[53]  R. Laskawi,et al.  Reduction of Salivary Flow With Botulinum Toxin: Extended Report on 33 Patients with Drooling, Salivary Fistulas, and Sialadenitis , 2004, The Laryngoscope.

[54]  S. Perez Lloret,et al.  Validation of a new scale for the evaluation of sialorrhea in patients with Parkinson's disease , 2007, Movement disorders : official journal of the Movement Disorder Society.

[55]  F. Gabreëls,et al.  A systematic review for evidence of efficacy of anticholinergic drugs to treat drooling , 2003, Archives of disease in childhood.

[56]  J. Rotteveel,et al.  The Treatment of Posterior Drooling by Botulinum Toxin in a Child with Cerebral Palsy , 2005, Journal of Pediatric Gastroenterology and Nutrition - JPGN.

[57]  A. Friedman,et al.  Controlling sialorrhoea: a review of available treatment options , 2005, Expert opinion on pharmacotherapy.

[58]  P Mertens,et al.  Subthalamic nucleus stimulation in Parkinson's disease , 2002, Journal of Neurology.

[59]  T. Osterberg,et al.  Influence of Parkinson's disease on oral health. , 1992, Acta odontologica Scandinavica.

[60]  Y. Agid,et al.  Stimulation of the subthalamic nucleus in Parkinson’s disease: a 5 year follow up , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[61]  E. Quigley,et al.  Gastrointestinal symptoms in Parkinson's disease , 1991, Movement disorders : official journal of the Movement Disorder Society.

[62]  R. Wilson,et al.  Salivary symptoms in Parkinson disease. , 1973, Archives of neurology.

[63]  Dorothy Tscheng.  Sialorrhea — Therapeutic Drug Options , 2002, The Annals of pharmacotherapy.

[64]  M. Woodward,et al.  Asymptomatic swallowing disorders in elderly patients with Parkinson's disease: a description of findings on clinical examination and videofluoroscopy in sixteen patients. , 1994, Age and ageing.

[65]  J. Sheode,et al.  Transtympanic neurectomies for control of drooling. , 1984, Auris, nasus, larynx.

[66]  L. Schneyer,et al.  Rate of secretion by individual salivary gland pairs of man under conditions of reduced exogenous stimulation. , 1955, Journal of applied physiology.

[67]  L. Provinciali,et al.  Botulinum toxin type A for drooling in Parkinson's disease: A double‐blind, randomized, placebo‐controlled study , 2006, Movement disorders : official journal of the Movement Disorder Society.

[68]  D. Reddihough,et al.  EFFECT OF ANTIREFLUX MEDICATION ON SALIVARY DROOLING IN CHILDREN WITH CEREBRAL PALSY , 1996, Developmental medicine and child neurology.

[69]  M. Borg,et al.  The role of radiation therapy in the management of sialorrhea. , 1998, International journal of radiation oncology, biology, physics.

[70]  A. Eisen,et al.  Use of radiotherapy for control of sialorrhea in patients with amyotrophic lateral sclerosis. , 2001, The Journal of otolaryngology.

[71]  H. Fischer-Brandies,et al.  Castillo‐Morales' Orofacial Therapy: Treatment of 67 Children with Down Syndrome , 1991, Developmental Medicine & Child Neurology.

[72]  M. De,et al.  Outcomes of submandibular duct relocation: a 15-year experience , 2003, The Journal of Laryngology & Otology.

[73]  G. Nappi,et al.  Double‐blind, placebo‐controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism , 2003, Movement disorders : official journal of the Movement Disorder Society.